Cargando…

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy

Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting on the role of the chronologically preceding agents, interferon-alfa and lamivudine. The impact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varbobitis, Ioannis, Papatheodoridis, George V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066383/ https://www.ncbi.nlm.nih.gov/pubmed/27729632 http://dx.doi.org/10.3350/cmh.2016.0045

Ejemplares similares

Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma
por: Bousali, Maria, et al.
Publicado: (2021)

Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy
por: Kotsiri, Ioanna, et al.
Publicado: (2016)

The Significance of Circulating Cell-Free DNA Markers in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Papatheodoridi, Alkistis, et al.
Publicado: (2021)

Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy
por: Seo, Yeon Seok, et al.
Publicado: (2016)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy: Erratum
Publicado: (2016)

The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking
por: Kanellopoulou, Theoni, et al.
Publicado: (2016)

Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
por: Thiele, Maja, et al.
Publicado: (2013)

Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib
por: Simão, Adélia
Publicado: (2016)

Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy
por: Alshuwaykh, Omar, et al.
Publicado: (2022)

Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure
por: Lee, I-Cheng, et al.
Publicado: (2017)

Predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy: Validating the CAMD and AASL scores in China
por: Wang, Shuai, et al.
Publicado: (2022)

Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B
por: Papatheodoridis, George V., et al.
Publicado: (2021)

Indefinite antiviral therapy may be required after surgical resection for hepatocellular carcinoma complicating chronic hepatitis B
por: Wei, Qiang, et al.
Publicado: (2013)

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients
por: Wu, Xiaoning, et al.
Publicado: (2023)

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy
por: Ke, Yang, et al.
Publicado: (2013)

Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
por: Kim, Sung Eun
Publicado: (2017)

Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B
por: Shin, Haneulsaem, et al.
Publicado: (2019)

Current Antiviral Therapy for Chronic Hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2004)

Antiviral therapy for chronic hepatitis B in China
por: Zheng, Xin, et al.
Publicado: (2014)

Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
por: Kim, In Jung, et al.
Publicado: (2022)

Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
por: Lee, Jae Seung, et al.
Publicado: (2021)

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
por: Ahn, Young-Hwan, et al.
Publicado: (2021)

Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia
por: Wang, Xinhui, et al.
Publicado: (2021)

Improved on-treatment fibrosis-4 during antiviral therapy and lower hepatocellular carcinoma risk in cirrhotic patients with hepatitis B
por: Oh, Joo Hyun, et al.
Publicado: (2023)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
por: Papatheodoridi, Margarita, et al.
Publicado: (2020)

Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy
por: Moon, Jin Chang, et al.
Publicado: (2015)

Elastography for Hepatic Fibrosis Severity in Chronic Hepatitis B or C
por: Papageorgiou, Maria-Vasiliki, et al.
Publicado: (2011)

Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
por: Shim, Jae-Jun, et al.
Publicado: (2016)

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
por: Sohn, Won, et al.
Publicado: (2017)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
por: Chien, Rong-Nan, et al.
Publicado: (2022)

Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B
por: Laras, Andreas, et al.
Publicado: (2022)

Impact of Interferon-α Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma
por: Karamitros, Timokratis, et al.
Publicado: (2018)

Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma
por: Wang, Peng, et al.
Publicado: (2023)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
por: Leal, Cassia, et al.
Publicado: (2023)

Sofosbuvir: a novel oral agent for chronic hepatitis C
por: Cholongitas, Evangelos, et al.
Publicado: (2014)

Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
por: Kim, David Sooik, et al.
Publicado: (2021)

Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals
por: Shi, Ke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pi5et43n8cvsl3iurqs89to8ua